Replies to post #819264 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

They would have told institutional investors before making it public in my opinion . Having absolutely zero impact on SP says a lot about buying interest or confidence.

[LessIsMore]

it is also very likely it is an important stepping stone

This is simply a pay-to-play report, any projection, forecast or price target has zero credibility.

They could've saved lots of money by having Gary project another $20 price target or better yet Flip could've reiterated his $73 projection for 2023.

[Chiugray]

I will add one more point. First Berlin’s report breaks the “retail-only” barrier that defines NWBO currently. They are a reputable European firm. By initiating coverage on an OTC and penny stock, they break the ice and set the stage for other international analysts and Wall Street to follow.

Aside from the rNPV, the $1.00 is just an initial price target. In the check-the-box world of Fund/Institutional investment committees, there is an “investable” milestone or threshold. They go through a Discovery > Monitoring > Staged Entry.

This First Berlin report provides the credibility required for the Discovery phase.
Monitoring would be seeing the thesis play out: MHRA Approval, $1 initial price, Flaskworks rollout, etc.

(In other words, even if their ultimate valuation is significantly higher, these analysts would use this $1 initial target as a tactical entry point, allowing them to "step up" their price expectations as each regulatory milestone is cleared.)